Sanctuary Advisors LLC Invests $784,000 in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Sanctuary Advisors LLC purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 16,441 shares of the company's stock, valued at approximately $784,000.

A number of other hedge funds also recently made changes to their positions in the business. Mather Group LLC. increased its position in Ionis Pharmaceuticals by 35.8% in the 2nd quarter. Mather Group LLC. now owns 911 shares of the company's stock valued at $39,000 after acquiring an additional 240 shares during the period. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Ionis Pharmaceuticals by 3.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,624 shares of the company's stock valued at $363,000 after purchasing an additional 261 shares during the period. Natixis Advisors LLC raised its stake in shares of Ionis Pharmaceuticals by 1.6% during the second quarter. Natixis Advisors LLC now owns 23,404 shares of the company's stock valued at $1,115,000 after purchasing an additional 376 shares in the last quarter. E Fund Management Co. Ltd. lifted its holdings in Ionis Pharmaceuticals by 4.4% in the second quarter. E Fund Management Co. Ltd. now owns 10,255 shares of the company's stock worth $489,000 after purchasing an additional 430 shares during the period. Finally, Amalgamated Bank grew its position in Ionis Pharmaceuticals by 4.9% in the 2nd quarter. Amalgamated Bank now owns 9,657 shares of the company's stock valued at $460,000 after buying an additional 454 shares in the last quarter. Institutional investors own 93.86% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on IONS shares. Leerink Partnrs upgraded shares of Ionis Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, July 24th. Bank of America boosted their price objective on Ionis Pharmaceuticals from $67.00 to $68.00 and gave the stock a "buy" rating in a research note on Tuesday, July 23rd. Leerink Partners raised Ionis Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their target price for the company from $53.00 to $62.00 in a research note on Wednesday, July 24th. Stifel Nicolaus upped their price target on shares of Ionis Pharmaceuticals from $50.00 to $53.00 and gave the company a "hold" rating in a report on Thursday, June 27th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Ionis Pharmaceuticals from $50.00 to $55.00 and gave the stock a "neutral" rating in a research note on Monday, August 26th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $60.28.

Insider Activity at Ionis Pharmaceuticals

In related news, EVP Richard S. Geary sold 2,430 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $48.00, for a total value of $116,640.00. Following the transaction, the executive vice president now directly owns 85,508 shares of the company's stock, valued at $4,104,384. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Ionis Pharmaceuticals news, EVP Richard S. Geary sold 2,430 shares of the company's stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $48.00, for a total value of $116,640.00. Following the completion of the transaction, the executive vice president now owns 85,508 shares of the company's stock, valued at $4,104,384. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Joseph Klein III sold 12,000 shares of the firm's stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $50.00, for a total transaction of $600,000.00. Following the completion of the transaction, the director now owns 16,346 shares of the company's stock, valued at approximately $817,300. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 14,750 shares of company stock valued at $732,371 over the last quarter. 2.71% of the stock is owned by corporate insiders.

Ionis Pharmaceuticals Trading Up 1.3 %

Shares of Ionis Pharmaceuticals stock traded up $0.49 during trading on Friday, hitting $38.44. 1,264,921 shares of the company were exchanged, compared to its average volume of 1,332,078. The company has a debt-to-equity ratio of 4.67, a current ratio of 7.61 and a quick ratio of 7.51. The firm has a market capitalization of $5.61 billion, a P/E ratio of -14.40 and a beta of 0.38. The firm's fifty day moving average price is $44.06 and its 200 day moving average price is $43.41. Ionis Pharmaceuticals, Inc. has a 1-year low of $35.95 and a 1-year high of $54.44.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.47. The business had revenue of $225.00 million for the quarter, compared to analysts' expectations of $152.35 million. Ionis Pharmaceuticals had a negative return on equity of 115.66% and a negative net margin of 44.90%. Ionis Pharmaceuticals's revenue for the quarter was up 19.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.60 EPS. As a group, sell-side analysts expect that Ionis Pharmaceuticals, Inc. will post -3.68 earnings per share for the current fiscal year.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.